CD274 and small cell lung carcinoma: A pooled analysis (17) from KEYNOTE-028 and KEYNOTE-158 indicated durable antitumor activity of pembrolizumab in patients with relapsed or metastatic SCLC who had received two or more prior lines of therapy, irrespective of PD-L1 expression.